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Abstract
Background Hypoglycaemia is the most frequent complication of treatment with insulin or insulin secretagogues in
people with diabetes. Severe hypoglycaemia, i.e. an event requiring external help because of cognitive dysfunction, is
associated with a higher risk of adverse cardiovascular outcomes and all-cause mortality, but underlying mechanism(s)
are poorly understood. There is also a gap in the understanding of the clinical, psychological and health economic impact
of ‘non-severe’ hypoglycaemia and the glucose level below which hypoglycaemia causes harm.
Aim To increase understanding of hypoglycaemia by addressing the above issues over a 4-year period.
Methods Hypo-RESOLVE is structured across eight work packages, each with a distinct focus. We will construct a
large, sustainable database including hypoglycaemia data from >100 clinical trials to examine predictors of
hypoglycaemia and establish glucose threshold(s) below which hypoglycaemia constitutes a risk for adverse biomedical
and psychological outcomes, and increases healthcare costs. We will also investigate the mechanism(s) underlying the
antecedents and consequences of hypoglycaemia, the significance of glucose sensor-detected hypoglycaemia, the impact
of hypoglycaemia in families, and the costs of hypoglycaemia for healthcare systems.
Results The outcomes of Hypo-RESOLVE will inform evidence-based definitions regarding the classification of
hypoglycaemia in diabetes for use in daily clinical practice, future clinical trials and as a benchmark for comparing glucose-
lowering interventions and strategies across trials. Stakeholders will be engaged to achieve broadly adopted agreement.
Conclusion Hypo-RESOLVE will advance our understanding and refine the classification of hypoglycaemia, with the
ultimate aim being to alleviate the burden and consequences of hypoglycaemia in people with diabetes.
Diabet. Med. 00, 1–8 (2020)
Background
Diabetes is a major non-communicable threat to global
health, affecting 10% of adults worldwide [1], and is among
the most expensive chronic health conditions, imposing an
increasing burden on healthcare resources [2]. Despite
different underlying causes and approaches to treatment,
both type 1 and type 2 diabetes can have devastating effects
on physical and mental health and can continue to reduce
both quality of life and life expectancy. Maintaining glucose
at or close to recommended target levels has been shown to
decrease risks of microvascular and macrovascular compli-
cations [3–7], and improves overall survival in people with
recent-onset type 2 diabetes [6].
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Insulin and insulin secretagogues (e.g. sulfonylureas) are
effective in managing hyperglycaemia, but increase hypogly-
caemia risk because their action is independent of glycaemic
levels. Hypoglycaemia causes profound physiological and
cellular stress, with marked stimulation of the autonomic
nervous system and the hypothalamic–pituitary–adrenal axis,
leading tosymptomsranging fromfeelingsofunpleasantness to
cognitive impairment, seriousharmordeath. In type1diabetes,
4–8% of premature deaths have been attributed to hypogly-
caemia [8,9], not including the so-called ‘dead-in-bed’ syn-
drome, a mode of sudden death thought to result from
hypoglycaemia-induced fatal arrhythmia [10]. Severe hypo-
glycaemia, defined as an event causing sufficient cognitive
dysfunction to require assistance from another person for
recovery [11], is predictive of two- to threefold higher risks of
cardiovascular morbidity and mortality in people with type 2
diabetes [12]. A recent analysis calculated that an unrealisti-
cally high prevalence of comorbid diseases would be needed to
explaintheassociationbyfrailtyalone[13],yet themechanisms
underlying a causative relationship remain undiscovered.
On average, hypoglycaemia occurs at a rate of two events
per week in those with type 1 and two per month in those
with insulin-treated type 2 diabetes [14]. Reported rates of
severe hypoglycaemia vary between 0.3 and 3 events per year
in unselected cohorts of people with type 1 diabetes [15]. The
distribution is highly skewed to those with impaired aware-
ness of hypoglycaemia [16,17], a condition already recog-
nized early following the discovery of insulin [18] and
characterized by reduced ability to detect the onset of
hypoglycaemia. Most estimates ignore ‘silent’ events that
occur in these individuals or during sleep. Significant
advances in diabetes management (e.g. insulin analogues,
subcutaneous pumps, glucose sensor technology and struc-
tured education) appear to have had only a relatively modest
impact on the incidence of hypoglycaemia [19].
The myriad of definitions for hypoglycaemia contribute to
the variation in reported incidence rates of hypoglycaemia.
The glucose cut-offs below which counter-regulatory
responses to, and symptoms of, hypoglycaemia appear are
not fixed and depend on both non-modifiable factors (e.g. age
and duration) and modifiable factors (e.g. prior exposure to
hyper- and hypoglycaemia) [20,21]. Despite agreement about
the clinical relevance of any event of low plasma glucose that
carries the potential to cause harm [22], uncertainty remains
about where such harm starts and in whom,making it difficult
to assign a single glucose threshold value to define hypogly-
caemia. The International Hypoglycaemia Study Group
(IHSG) has proposed a three-level classification: level 1:
glucose ≤3.9 mmol/l (70 mg/dl), representing an alert value;
level 2: glucose <3.0 mmol/l (54 mg/dl) to indicate ‘clinically
important hypoglycaemia’, based on its association with
cognitive dysfunction, reductions in hypoglycaemic awareness
and mortality; and level 3: severe hypoglycaemia, as defined
above [11]. This classification has been adopted by the
American Diabetes Association, the European Association
for the Study of Diabetes, the International Society for
Paediatric and Adolescent Diabetes [23] and the European
Medicines Agency (EMA), and by an international expert
panel on continuous glucose monitoring [24].
The evidence base supporting this classification remains
relatively limited [25], particularly with respect to interstitial
glucose measurements, which is relevant given the increasing
use of glucose sensors, both clinically and in trials. Also, data
on the health-economic consequences and on patient-reported
outcomes related to ‘non-severe’ hypoglycaemia are largely
lacking, but highly relevant in clinical practice, as hypogly-
caemia affects virtually everyone using insulin. Thus, there is
an urgent need to increase understanding of hypoglycaemia in
diabetes and to provide more robust and comprehensive
evidence to strengthen and/or refine the IHSG-proposed
classification.
Project aim
The Hypoglycaemia REdefining SOLutions for better liVEs
(Hypo-RESOLVE) project’s overall aim is to reduce the
burden and consequences of hypoglycaemia in people with
diabetes by increasing our understanding of hypoglycaemia,
using a comprehensive multilevel approach that addresses
unanswered questions and unmet needs [26]. In the present
paper, we explain how clinicians and scientists with expertise
in basic, clinical, psychological/behavioural and health-eco-
nomic aspects of hypoglycaemia will work collaboratively
with data science and biostatistics experts, industry partners,
people with diabetes, healthcare organizations and other
stakeholders to achieve this aim.
Project outline
The work of Hypo-RESOLVE is structured across eight work
packages (WPs), each of which has a distinct (scientific)
focus, with strong interconnected linkages (Fig. 1). Central to
the project is the further elucidation of the link between
hypoglycaemia, whether measured by finger pricks or con-
tinuous glucose monitoring, and clinical (i.e. cardiovascular
and mortality) consequences, its underlying mechanism(s),
and patient-reported and health-economic outcomes. We will
also map definitions of hypoglycaemia as they are currently
being used in national and international guidelines and
maintain a close dialogue with regulators, including the
EMA, and other stakeholders.
Hypo-RESOLVE database: WP3 and WP4
It is standard practice for hypoglycaemic events to be
secondary or safety outcomes in clinical trials involving
insulin treatment. A key objective of Hypo-RESOLVE is to
collect these events alongside a range of clinical outcomes
from over 100 clinical trials on insulin treatment and/or
glucose monitoring in people with type 1 or type 2 diabetes,
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to construct a large, sustainable database, offering the
statistical power needed to establish the glucose threshold
(s) below which hypoglycaemia constitutes a risk. Entry
criteria for these trials are: randomized trials initiated in
2001 or later; participants with type 1 or type 2 diabetes;
insulin treatment alone or in combination with other drugs;
and trial duration of at least 12 weeks. After a process of de-
identification to ensure participant anonymity, original data
from each trial will be extracted, reformatted and harmo-
nized to the standard Clinical Data Interchange Standards
Consortium (CDISC) Study Data Tabulation Model (SDTM)
format (http://www.cdisc.org/; Fig. 2). De-identified trial
data will be uploaded to a secure server behind a firewall,
inaccessible for downloads or changes, and subsequently
harmonized and pooled into a single database, reachable for
a variety of statistical analysis tools, implemented in the R
statistical framework. After agreeing on categorization of
hypoglycaemia, e.g. defined by presence (or absence) of
symptoms, help from another person, certain glucose thresh-
olds and duration, the associations with (un)known clinical
and psychological consequences will be examined. A statis-
tical analysis plan is being constructed and tested to perform
analyses on the risk factors for, and consequences of,
hypoglycaemia. Using data from the Scottish Diabetes
Research Network Type 1 Bioresource [27], a Bayesian
posterior distribution method was found to be a better fit to
model the risk factors for the prediction of hypoglycaemia
than the standard approach of negative binomial regression
(manuscript in preparation).
Mechanistic studies: WP2
The focus of basic research will be first on further elucidation
of the pathogenesis of impaired awareness of hypoglycaemia.
Animal studies with state-of-the-art transgenic approaches
will also be used to discover novel pathways that contribute
to the development of impaired awareness of hypoglycaemia
as well as to identify therapeutic targets that may help to
restore hypoglycaemia awareness.
A second crucial element of the project is to reveal the
potential mechanism(s) underlying the association between
(severe) hypoglycaemia and cardiovascular outcomes, which
would complement analyses of the above-mentioned Hypo-
RESOLVE clinical database. Recent research has shown
hypoglycaemia to be a pro-inflammatory, potentially pro-
atherogenic, stimulus [28], with the resulting response
potentially modifiable by prior exposure to hypoglycaemia
or the level of overall glucose control. We will characterize in
detail the nature and time course of such inflammatory
responses, including underlying processes, using hyperinsuli-
naemic hypoglycaemic glucose clamps. During and up to 1
week after the clamp, blood will be sampled and immune
cells isolated for extensive phenotyping. The primary out-
come is the effect of experimental hypoglycaemia on inflam-
matory responses; secondary outcomes include underlying
molecular, metabolic and functional mechanisms, epigenetic
profiles and oxidative stress, as well as cardiac function,
assessed by echocardiography. The experiments will be
conducted in people with: type 1 diabetes with intact
awareness of hypoglycaemia; type 1 diabetes with impaired
awareness of hypoglycaemia; type 1 diabetes with subopti-
mal glycaemia (HbA1c >64 mmol/mol [8%]); and insulin-
treated type 2 diabetes (n=16 each). One group of volunteers
without diabetes (n=16), matched to those with type 2
diabetes, will undergo the same procedure. Another group
(n=32), matched to participants with type 1 diabetes, will be
randomized to prior exposure to either two episodes of
hypoglycaemia or normoglycaemia on the day before the
FIGURE 1 Organizational structure and interaction of the work in Hypo-RESOLVE: project management [work package (WP)1], animal and human
pre-clinical experiments (WP2), construction of the sustainable Hypo-RESOLVE database (WP3), analysis of the Hypo-RESOLVE database to refine
and solidify the classification of hypoglycaemia (WP4), glucose monitoring studies (WP5), psychological burden of hypoglycaemia (WP6), health-
economic impact of hypoglycaemia (WP7) and interaction with stakeholders and engagement with people affected by or living with diabetes (WP8).
ª 2020 The Authors.
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clamp procedure. Sample sizes are based on a power
calculation to meet the primary outcome for each subgroup
separately, with comparisons between groups to be con-
ducted in subsequent analyses. The broad inclusion criteria
of this study, registered at clinicaltrials.gov (NCT03976271),
will enable us to assess the impact of awareness of hypogly-
caemia, HbA1c, prior hypoglycaemia and duration of dia-
betes. Moreover, complimentary rodent studies will
determine whether the effects in immune cells are replicated
in specific organs (e.g. the heart) and tissues (e.g. adipose
tissue), and to examine the impact of recurrent hypogly-
caemia on end-organ histopathology and function.
Using continuous glucose monitoring to understand
hypoglycaemia: WP5
In the management of insulin-treated diabetes, self-monitor-
ing of blood glucose, with its major limitations of (relatively)
infrequent glucose measurements at (more or less) standard
time points, is being superseded by (semi-)continuous glucose
monitoring techniques. In the near future, these techniques
will become increasingly important for monitoring glucose
levels and patterns, assessing glycaemic targets and evaluat-
ing the effects of interventions, particularly in type 1 diabetes
and in countries where individuals or the healthcare system
can afford it. As continuous glucose monitoring starts to
become used as an outcome measure to determine risk of
hypoglycaemia, we also recognize that device metrics may be
unstable over short durations. Glucose sensor data collected
and harmonized in the constructed database (WP3) will
enable analysis of the optimum duration of glucose sensor
use and the relative contribution of sampling interval to
determine an individual’s risk of hypoglycaemia. We will use
in silico modelling techniques to glucose sensor data to
identify behavioural factors, including self-monitoring of
blood glucose, carbohydrate counting and missed insulin
administration, that modify the risk of hypoglycaemia.
Recent data show that, even in those with intact awareness
of hypoglycaemia, up to 60% of episodes are asymptomatic
and undetected by the individual [29]. This causes a clinical
dilemma as to whether such events need to be treated or
ignored, and raises issues about how people deal, psycho-
logically, with visibility of the potentially overwhelming
amount of (semi-)continuous data. We will therefore conduct
a multinational observational study aiming to understand the
impact of both symptomatic and asymptomatic episodes of
low glucose sensor readings. Participants will be asked to
wear blinded glucose sensors for 10 weeks, in addition to
their usual means of glucose monitoring. They will also use
an app to register all self-treated episodes of hypoglycaemia
and answer questions in real-time relevant to various
domains of life that may be affected by hypoglycaemia.
The primary objective is to determine the optimal definition
of sensor hypoglycaemia in terms of threshold and duration
FIGURE 2 Workflow for the construction of the Hypo-RESOLVE database. API, application programming interface; WP, work package.
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by elucidating the optimum value of these variables that
provides the best sensitivity and specificity for patient-
reported hypoglycaemia. Secondary outcomes include the
impact of symptomatic as well as asymptomatic hypogly-
caemia and low interstitial glucose values on clinical,
psychosocial and health-economic variables, such as activity,
sleep quality, energy levels, well-being, quality of life and
productivity. A sample size calculation based on the number
of expected episodes of patient-reported hypoglycaemia and
sensor-detected hypoglycaemia taken from a series of large
observational datasets, calculated that 180 adults with type 1
and 325 with type 2 diabetes are required to meet our
primary objective. Allowing for withdrawals and to be able
to evaluate outcomes in those with impaired awareness, we
aim to recruit 250 participants with type 1 diabetes, 50 of
whom have impaired awareness, and 350 with type 2
diabetes (n=600 in total). We will investigate differences in
the impact of hypoglycaemia between type 1 and type 2
diabetes, and the impact of other aspects such as sleep and
baseline hypoglycaemia rate on these factors.
Psychological burden and health-economic impact: WP6 and
WP7
The potential of hypoglycaemia to cause cognitive decline,
social embarrassment, loss of consciousness, accidents and
physical injury is a well-known cause of fear of hypogly-
caemia [30] among individuals with diabetes, as well as
partners, parents and other family members [31,32]. Sub-
stantial fear of hypoglycaemia often results in a coping
strategy of maintaining glucose levels in the higher range,
thus accepting increased exposure to hyperglycaemia and
greater risks of associated vascular complications [33].
Indisputably, hypoglycaemia (and the fear of it) remains a
major barrier to people with diabetes achieving and main-
taining the glucose levels necessary to avoid the long-term
complications associated with chronic hyperglycaemia [34].
To achieve better insight into the overall burden of
hypoglycaemia for people with diabetes and their families,
extensive systematic literature reviews will be performed to
collate and critique all quantitative and qualitative studies
investigating the impact of hypoglycaemia on quality of life
and associated psychological outcomes among adults or
children with diabetes and family members. Findings will be
summarized and, where possible, subjected to meta-analyses.
Existing patient-reported outcome instruments relevant to
assessing the burden of hypoglycaemia will be identified, and
their psychometric characteristics will be summarized and
critiqued. This knowledge will be used to develop new or
refine existing patient-reported outcome instruments that can
be used in various populations for health-economic evalua-
tion purposes. In addition, these instruments will be devel-
oped into a preference-based measure, such that it can be
used to generate quality-adjusted life-years for use in cost–
utility analyses. As such, Hypo-RESOLVE will be able to
precisely map the health-economic consequences of hypo-
glycaemia, including the costs of hypoglycaemia for health-
care systems in Europe and elsewhere.
In parallel, a qualitative multi-country online survey will
be conducted to explore the unmet psychological needs of
people with diabetes and their families in relation to the
prevention, experience and management of hypoglycaemia.
We plan to include 800–1000 participants from Denmark,
Germany, the Netherlands and the UK, stratified into groups
of adults with type 1 or type 2 diabetes, children and
adolescents with diabetes, and family members. The findings
will subsequently be used to design a multinational quanti-
tative online survey to further address knowledge gaps,
including the impact of (severe and self-treated) hypogly-
caemia in adults and adolescents and on relationships, unmet
care needs and barriers to talking about hypoglycaemia.
Integration of the results of Hypo-RESOLVE: WP8
The findings from Hypo-RESOLVE will be collated into a
comprehensive summary for high-level communication with
stakeholders and development of a consensus guideline with
uniformly agreed definitions and data collection methods for
the standardization of clinical investigations with regard to
hypoglycaemia. A dialogue has thus been established with
key European and American regulators, Health Technology
Assessment (HTA) body representatives, professional and
diabetes organizations and other stakeholders.
Project organization: WP1
The Hypo-RESOLVE consortium comprises 23 partner orga-
nizations from academic centres across Europe, industry and
biotech partners owning the vast majority of global insulin
producing capacity and the manufacturing of glucose moni-
toring devices, respectively, organizations representing people
with diabetes, and a project management office. A multi-
layered governance model has been agreed to ensure suitable
levels of cooperation, scientific exchange and project manage-
ment, as well as a decision-making process, in order to achieve
the project’s objectives. An international Patient Advisory
Committee has been formed that interacts closely with each of
the WPs to ensure that the voice of people with diabetes
resonates in the direction, goals and strategy of the project.
Finally, multi-disciplinary Strategic Advisory and Ethics
Boards have been appointed to provide reflection and feedback
from scientific and ethical perspectives, respectively.
Expected impact
Usingdetailedandvaried statistical analyses,Hypo-RESOLVE
will provide robust evidence about risk factors and clinical,
psychological and health-economic consequences of asymp-
tomatic (i.e. sensor-detected), non-severe and severe hypogly-
caemia in peoplewith diabetes. Integration of these data offers
ª 2020 The Authors.
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the unique opportunity to refine and solidify an evidence-based
classification of hypoglycaemia, whether measured in (capil-
lary) blood or the interstitium, for its use in clinical practice,
trials design and research, and for the development of clinical
guidelines.TheresultsofHypo-RESOLVEareexpectedtobeof
considerable interest to a broad range of stakeholders, includ-
ingpeoplewithdiabetes,healthcareprofessionals, the scientific
community, HTA bodies, regulators, industry and payers
(Table 1). The project’s progress will be reported through
scientific publications, the Hypo-RESOLVE website (hypo-
resolve.eu), social media (@HypoResolve), and stakeholder
meetings, to ensure widespread dissemination to, and engage-
ment with, all those potentially interested in the project’s
progress and outcomes and to endorse the ramifications of its
analyses for classifying hypoglycaemia.
Hypo-RESOLVE limitations
Although comprehensive, Hypo-RESOLVE will not provide
answers to all questions relating to hypoglycaemia in people
withdiabetes. Inparticular, theHypo-RESOLVEdatabasemay
be (too) limited for directly examining harmof sensor-detected
hypoglycaemia and investigating hypoglycaemia in certain
populations. Children, the elderly, pregnant women, ethnic
subgroupsandpeopleathighest riskof (severe)hypoglycaemia,
including those with impaired awareness of hypoglycaemia,
chronic kidney disease or other chronic comorbidities are
usually excluded frommost clinical trials. However, the harm
of sensor-detected hypoglycaemia may be derived indirectly
from the observational clinical study on continuous glucose
monitoring. Also, examining the impact of hypoglycaemia on
children, and in particular their carers, is a specific objective of
the ‘psychology’ WP, whereas elderly populations will be
included in the health-economic work. Finally, people with
impaired awareness of hypoglycaemia will be recruited to the
experimental, psychological and clinical studies, and animal
studies will include models of this condition.
Conclusion
Despite almost 100 years of experience with insulin as a
treatment for diabetes and major advances in its
Table 1 Expected impact of Hypo-RESOLVE for stakeholders
Stakeholder Expected impact
People with
diabetes
 Facilitating patient–clinician interaction when discussing glucose-lowering interventions that affect risk of
hypoglycaemia
 Assessment of risk of hypoglycaemia at the individual level
 More support in relationships with partners, family members, co-workers and friends
 Better appreciation of indirect costs of (non-severe) hypoglycaemia, such as overall functioning, sleep, well-being,
quality of life, productivity and work-related absenteeism and presenteeism
 Advancement of personalised glucose management
Healthcare
professionals
 Improved knowledge of clinical and psychological impact of hypoglycaemia (at various levels)
 Better appreciation of trial outcomes
 More insight into the pathways underlying hypoglycaemia-sensing and impaired awareness of hypoglycaemia
 Equipped healthcare professionals better to discuss treatment choices with people with diabetes and their family
members
Payers  Calculation of the overall costs of the hypoglycaemic burden
 Enabling more accurate cost-effectiveness of interventions aimed at improving glucose control
 Help with directing resources to where they can be used the most efficiently
Regulatory
authorities
 Better understanding of the clinical, psychological and health-economic impact of hypoglycaemia, and of valid
assessment tools
 Facilitating the conduct and use of meta-analyses to compare both efficacy and (hypoglycaemic) safety of glucose-
lowering interventions
 Providing strong evidence base for development of guidelines and its adoption by other stakeholders, including
payers
Scientific
community
 Further delineation of mechanisms underlying the link between hypoglycaemia and cardiovascular risks
 Setting the standard for glucose levels to be used in experimental hypoglycaemia research (e.g. clamps)
 Invitation to scientists to use the constructed Hypo-RESOLVE database to answer new research questions
Industry  Enabling better comparisons of glucose-lowering interventions and strategies across trials and benchmarking
industry’s products against those of competitors
 Harmonization of hypoglycaemia measures by SMBG or CGM will inform the industry how to best apply CGM in
future clinical trials
 Discovering new targets for intervention will open avenues for the development of novel hypoglycaemic risk
reducing pharmaceutical agents and technological solutions
 Helping to better define populations most in need of hypoglycaemia risk reducing interventions in clinical trials
CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose.
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management, hypoglycaemia remains a continuous threat to
people with diabetes who require treatment with insulin or
secretagogues. The clinical, psychological and health-eco-
nomic consequences of hypoglycaemia and, in particular, the
glucose threshold identifying increased risk for harm, remain
to be fully established. Hypo-RESOLVE will apply a
comprehensive multi-level, multi-disciplinary scientific
approach to examine the links between hypoglycaemia (at
various levels) and potentially harmful outcomes and its
underlying mechanism(s), where applicable. Thus, Hypo-
RESOLVE will advance our understanding of hypogly-
caemia, so as to alleviate its burden and improve the lives
of all people affected by diabetes.
Funding sources
Hypo-RESOLVE has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking (JU) under grant
agreement No 777460. The JU receives support from the
European Union’s Horizon 2020 research and innovation
programme and EFPIA and T1D Exchange, JDRF, Interna-
tional Diabetes Federation (IDF) and The Leona M. and
Harry B. Helmsley Charitable Trust. The industry partners
supporting the JU include Abbott Diabetes Care, Eli Lilly,
Medtronic, Novo Nordisk and Sanofi-Aventis. The funder
had no role in the design of the project or its WPs, the
collection or analysis of data, the writing of the manuscript
or the decision to submit for publication.
Competing interests
B.D.G. has served on scientific advisory boards for Novo
Nordisk and received research grant support from Astra-
Zeneca and Sanofi. S.R.H. has served on advisory boards
for Eli Lilly, Novo Nordisk, Sanofi Aventis and Zealand
Pharma and been a member of speaker panels for Novo
Nordisk. R.J.M. has served on advisory boards for Eli Lilly,
Novo Nordisk, Sanofi Aventis and been a member of
speaker panels for Novo Nordisk. J.S. has served on the
advisory boards of Janssen, Medtronic, Roche Diabetes
Care and Sanofi Diabetes. Her research group (ACBRD) has
received honoraria in respect of these activities, and she has
also received unrestricted educational grants and in-kind
support from Abbott Diabetes Care, AstraZeneca, Med-
tronic, Roche Diabetes Care and Sanofi Diabetes, sponsor-
ship to attend educational meetings from Medtronic, Roche
Diabetes Care and Sanofi Diabetes, and consultancy income
and/or speaker fees from Abbott Diabetes Care, AstraZe-
neca, Medtronic, Novo Nordisk, Roche Diabetes Care and
Sanofi Diabetes. M.R. is an employee of Eli Lilly and
company. C.T. has served on scientific advisory boards for
Merck and Novo Nordisk and received research grant
support from AstraZeneca. M.M. is employee of Novo
Nordisk A/S. All other authors declare no conflicts of
interest.
References
1 International Diabetes Federation. IDF Diabetes Atlas. 8th edn.
Brussels: IDF, 2017.
2 Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J et al.
Global healthcare expenditure on diabetes for 2010 and 2030.
Diabetes Res Clin Pract 2010; 87: 293–301.
3 Intensive blood-glucose control with sulphonylureas or insulin
compared with conventional treatment and risk of complications in
patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes
Study (UKPDS) Group. Lancet 1998; 352: 837–853.
4 The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent
diabetes mellitus. The Diabetes Control and Complications Trial
Research Group. N Engl J Med 1993; 329: 977–986.
5 Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M,
Reaven P et al. Effects of intensive glucose control on microvas-
cular outcomes in patients with type 2 diabetes: a meta-analysis of
individual participant data from randomised controlled trials.
Lancet Diabetes Endocrinol 2017; 5: 431–437.
6 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year
follow-up of intensive glucose control in type 2 diabetes. N Engl J
Med 2008; 359: 1577–1589.
7 Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM,
Orchard TJ et al. Intensive diabetes treatment and cardiovascular
disease in patients with type 1 diabetes. N Engl J Med 2005; 353:
2643–2653.
8 Tunbridge WM. Factors contributing to deaths of diabetics under
fifty years of age. On behalf of the Medical Services Study Group
and British Diabetic Association. Lancet 1981; 2: 569–572.
9 Gagnum V, Stene LC, Jenssen TG, Berteussen LM, Sandvik L,
Joner G et al. Causes of death in childhood-onset Type 1 diabetes:
long-term follow-up. Diabet Med 2017; 34: 56–63.
10 Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypo-
glycemia in the "dead-in-bed" syndrome, as captured by a
retrospective continuous glucose monitoring system. Endocr Pract
2010; 16: 244–248.
11 International Hypoglycaemia Study Group. Glucose Concentra-
tions of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in
Clinical Trials: A Joint Position Statement of the American
Diabetes Association and the European Association for the Study
of Diabetes. Diabetes Care 2017; 40: 155–157.
12 Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L et al.
Severe hypoglycemia and risks of vascular events and death. N
Engl J Med 2010; 363: 1410–1418.
13 Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe
hypoglycaemia and cardiovascular disease: systematic review and
meta-analysis with bias analysis. BMJ 2013; 347: f4533.
14 International Hypoglycaemia Study Group. Minimizing Hypo-
glycemia in Diabetes. Diabetes Care 2015; 38: 1583–1591.
15 Pedersen-Bjergaard U, Thorsteinsson B. Reporting Severe Hypo-
glycemia in Type 1 Diabetes: Facts and Pitfalls. Curr Diab Rep
2017; 17: 131.
16 UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1
and 2 diabetes: effects of treatment modalities and their duration.
Diabetologia 2007; 50: 1140–1147.
17 Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of
severe hypoglycaemia and self-estimated state of awareness in type
1 diabetes. Diabetes Metab Res Rev 2003; 19: 232–240.
18 Lawrence RD. Insulin hypoglycaemia: changes in nervous mani-
festations. Lancet 1941; 2: 602–604.
19 Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ
et al. National trends in US hospital admissions for hyperglycemia
and hypoglycemia among Medicare beneficiaries, 1999 to 2011.
JAMA Intern Med 2014; 174: 1116–1124.
ª 2020 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 7
Trial Protocol DIABETICMedicine
20 Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE. Plasma
glucose concentrations at the onset of hypoglycemic symptoms in
patients with poorly controlled diabetes and in nondiabetics. N
Engl J Med 1988; 318: 1487–1492.
21 Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic
responses to subsequent hypoglycemia after 1 episode of hypo-
glycemia in nondiabetic humans. Diabetes 1991; 40: 223–226.
22 Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L
et al. Hypoglycemia and diabetes: a report of a workgroup of the
American Diabetes Association and the Endocrine Society. Dia-
betes Care 2013; 36: 1384–1395.
23 Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A,
Tauschmann M et al. ISPAD Clinical Practice Consensus Guide-
lines 2018: Assessment and management of hypoglycemia in
children and adolescents with diabetes. Pediatr Diabetes 2018;
19 (Suppl. 27): 178–192.
24 Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries
JH et al. International Consensus on Use of Continuous Glucose
Monitoring. Diabetes Care 2017; 40: 1631–1640.
25 Heller SR, Buse JB, Ratner R, Seaquist E, Bardtrum L, Hansen CT
et al. Redefining Hypoglycemia in Clinical Trials: Validation of
Definitions Recently Adopted by the American Diabetes Associa-
tion/European Association for the Study of Diabetes. Diabetes
Care 2019; pii: dc182361. https://doi.org/10.2337/dc18-2361.
[Epub ahead of print].
26 Hypo-RESOLVE Investigates Hypoglycaemia and its Impact in
Diabetes. Available at https://www.hypo-resolve.eu/. Last accessed
1 December 2019.
27 McKeigue PM, Spiliopoulou A, McGurnaghan S, Colombo M,
Blackbourn L, McDonald TJ et al. Persistent C-peptide secretion in
Type 1 diabetes and its relationship to the genetic architecture of
diabetes. BMC Med 2019; 17: 165.
28 Ratter JM, Rooijackers HM, Tack CJ, Hijmans AG, Netea MG, de
Galan BE et al. Proinflammatory Effects of Hypoglycemia in
Humans With or Without Diabetes. Diabetes 2017; 66: 1052–
1061.
29 Henriksen MM, Andersen HU, Thorsteinsson B, Pedersen-Bjer-
gaard U. Hypoglycemic Exposure and Risk of Asymptomatic
Hypoglycemia in Type 1 Diabetes Assessed by Continuous
Glucose Monitoring. J Clin Endocrinol Metab 2018; 103:
2329–2335.
30 Hendrieckx C, Halliday JA, Bowden JP, Colman PG, Cohen N,
Jenkins A, et al. Severe hypoglycaemia and its association with
psychological well-being in Australian adults with type 1 diabetes
attending specialist tertiary clinics. Diabetes Res Clin Pract 2014;
103: 430–436.
31 Gonder-Frederick L, Nyer M, Shepard JA, Vajda K, Clarke W.
Assessing fear of hypoglycemia in children with Type 1 diabetes
and their parents. Diabetes Manag (Lond) 2011; 1: 627–639.
32 Anderbro T, Gonder-Frederick L, Bolinder J, Lins PE, Wredling R,
Moberg E et al. Fear of hypoglycemia: relationship to hypo-
glycemic risk and psychological factors. Acta Diabetol 2015; 52:
581–589.
33 Gonder-Frederick LA, Vajda KA, Schmidt KM, Cox DJ, Devries
JH, Erol O et al. Examining the Behaviour subscale of the
Hypoglycaemia Fear Survey: an international study. Diabet Med
2013; 30: 603–609.
34 Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic
management of Type I and Type II diabetes. Diabetologia 2002;
45: 937–948.
8
ª 2020 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Understanding hypoglycaemia in diabetes  B. E. de Galan et al.
